4 May 2026 - Satellite Biosciences today announced that the US FDA has granted rare paediatric disease designation for SB-101 for the treatment of urea cycle disorders.

Satellite Bio’s lead program, SB-101, is a first in class off the shelf liver therapy being developed as a treatment for infants with severe early onset urea cycle disorders.

Read Satellite Bio press release